Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptors

Human Molecular Genetics

Volumn 24, Issue 2, 2015, Pages 314-329

  Iida, Madoka ^a   Katsuno, Masahisa ^a   Nakatsuji, Hideaki ^a   Adachi, Hiroaki ^a   Kondo, Naohide ^a   Miyazaki, Yu ^a   Tohnai, Genki ^a   Ikenaka, Kensuke ^a   Watanabe, Hirohisa ^a   Yamamoto, Masahiko ^b   Kishida, Ken ^c,d   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI GAKUIN UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Kishida Clinic ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANDROGEN RECEPTOR; CYTOCHROME C OXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; POLYGLUTAMINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; PEPTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; GENE EXPRESSION; GENE ONTOLOGY; GRIP STRENGTH; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KENNEDY DISEASE; MALE; MICROGLIA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MUSCLE ATROPHY; NERVE CELL DEGENERATION; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; ROTAROD TEST; SKELETAL MUSCLE; SPINAL CORD; SURVIVAL RATE; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MUSCULAR DISORDERS, ATROPHIC; NERVE CELL; TRINUCLEOTIDE REPEAT;

MUS; MUS MUSCULUS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SKELETAL; MUSCULAR DISORDERS, ATROPHIC; NEURONS; PEPTIDES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, ANDROGEN; SPINAL CORD; THIAZOLIDINEDIONES; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84922466241     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu445     Document Type: Article

References (66)

1. La Spada, A.R. and Taylor, J.P. (2010) Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat. Rev. Genet., 11, 247-258.
2. Kennedy, W.R., Alter, M. and Sung, J.H. (1968) Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology, 18, 671-680.
3. Sobue, G., Hashizume, Y., Mukai, E., Hirayama, M., Mitsuma, T. and Takahashi, A. (1989) X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain, 112, 209-232.
4. Katsuno, M., Tanaka, F., Adachi, H., Banno, H., Suzuki, K., Watanabe, H. and Sobue, G. (2012) Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog. Neurobiol., 99, 246-256.
5. Katsuno, M., Adachi, H., Kume, A., Li, M., Nakagomi, Y., Niwa, H., Sang, C., Kobayashi, Y., Doyu, M. and Sobue, G. (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron, 35, 843-854.
6. Minamiyama, M., Katsuno, M., Adachi, H., Doi, H., Kondo, N., Iida, M., Ishigaki, S., Fujioka, Y., Matsumoto, S., Miyazaki, Y. et al. (2012) Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract. Nat. Med., 18, 1531-1538.
7. Nedelsky, N.B., Pennuto, M., Smith, R.B., Palazzolo, I., Moore, J., Nie, Z., Neale, G. and Taylor, J.P. (2010) Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron, 67, 936-952.
8. Katsuno, M., Adachi, H., Minamiyama, M., Waza, M., Tokui, K., Banno, H., Suzuki, K., Onoda, Y., Tanaka, F., Doyu, M. et al. (2006) Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration. J. Neurosci., 26, 12106-12117.
9. Sorarù, G., D'Ascenzo, C., Polo, A., Palmieri, A., Baggio, L., Vergani, L., Gellera, C., Moretto, G., Pegoraro, E. and Angelini, C. (2008) Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J. Neurol. Sci., 264, 100-105.
10. Rhodes, L.E., Freeman, B.K., Auh, S., Kokkinis, A.D., La, P.A., Chen, C., Lehky, T.J., Shrader, J.A., Levy, E.W., Harris, L.M. et al. (2009) Clinical features of spinal and bulbar muscular atrophy. Brain, 132, 3242-3251.
11. Hashizume, A., Katsuno, M., Banno, H., Suzuki, K., Suga, N., Mano, T., Atsuta, N., Oe, H., Watanabe, H., Tanaka, F. et al. (2012) Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain, 135, 2838-2848.
12. Chevalier-Larsen, E.S., O'Brien, C.J., Wang, H., Jenkins, S.C., Holder, L., Lieberman, A.P. and Merry, D.E. (2004) Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J. Neurosci., 24, 4778-4786.
13. Palazzolo, I., Stack, C., Kong, L., Musaro, A., Adachi, H., Katsuno, M., Sobue, G., Taylor, J.P., Sumner, C.J., Fischbeck, K.H. et al. (2009) Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron, 63, 316-328.
14. Yu, Z., Dadgar, N., Albertelli, M., Gruis, K., Jordan, C., Robins, D.M. and Lieberman, A.P. (2006) Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J. Clin. Invest., 116, 2663-2672.
15. Lieberman, A.P., Zhang, Z., Wang, J., Zhang, C., Li, H. and Xu, Y. (2014) Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep., 7, 774-784.
16. Cortes, C.J., Ling, S.C., Guo, L.T., Hung, G., Tsunemi, T., Ly, L., Tokunaga, S., Lopez, E., Sopher, B.L., Bennett, C.F. et al. (2014) Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron, 82, 295-307.
17. Ranganathan, S., Harmison, G.G., Meyertholen, K., Pennuto, M., Burnett, B.G. and Fischbeck, K.H. (2009) Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum. Mol. Genet., 18, 27-42.
18. Beauchemin, A.M., Gottlieb, B., Beitel, L.K., Elhaji, Y.A., Pinsky, L. and Trifiro, M.A. (2001) Cytochrome c oxidase subunit Vb interacts with human androgen receptor: a potential mechanism for neurotoxicity in spinobulbar muscular atrophy. Brain Res. Bull., 56, 285-297.
19. Cui, L., Jeong, H., Borovecki, F., Parkhurst, C.N., Tanese, N. and Krainc, D. (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 127, 59-69.
20. Tontonoz, P. and Spiegelman, B.M. (2008) Fat and beyond: the diverse biology of PPARg. Annu. Rev. Biochem., 77, 289-312.
21. Storer, P.D., Xu, J., Chavis, J. and Drew, P.D. (2005) Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J. Neuroimmunol., 161, 113-122.
22. Gray, E., Ginty, M., Kemp, K., Scolding, N. and Wilkins, A. (2012) The PPAR-g agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function. J. Neuroinflammation, 9, 63.
23. Xu, F., Li, J., Ni, W., Shen, Y.W. and Zhang, X.P. (2013) Peroxisome proliferator-activated receptor-g agonist 15d-prostaglandin J2 mediates neuronal autophagy after cerebral ischemia-reperfusion injury. PLoSOne, 8, e55080.
24. Quintanilla, R.A., Jin, Y.N., Fuenzalida, K., Bronfman, M. and Johnson, G.V. (2008) Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J. Biol. Chem., 283, 25628-25637.
25. Mano, T., Katsuno, M., Banno, H., Suzuki, K., Suga, N., Hashizume, A., Tanaka, F. and Sobue, G. (2012) Cross-sectional and longitudinal analysis of an oxidative stress biomarker for spinal and bulbar muscular atrophy. Muscle Nerve, 46, 692-697.
26. Zhang, H.L., Xu, M., Wei, C., Qin, A.P., Liu, C.F., Hong, L.Z., Zhao, X.Y., Liu, J. and Qin, Z.H. (2011) Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-kB signaling pathway. Neuroscience, 176, 381-395.
27. Dehmer, T., Heneka, M.T., Sastre, M., Dichgans, J. and Schulz, J.B. (2004) Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappaBalpha induction and block of NF kappaB and iNOS activation. J. Neurochem., 88, 494-501.
28. Mandrekar-Colucci, S., Karlo, J.C. and Landreth, G.E. (2012) Mechanisms underlying the rapid peroxisome proliferator-activated receptor-g-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J. Neurosci., 32, 10117-10128.
29. Chawla, A. (2010) Control of macrophage activation and function by PPARs. Circ. Res., 106, 1559-1569.
30. Trushina, E. and McMurray, C.T. (2007) Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience, 145, 1233-1248.
31. Seong, I.S., Ivanova, E., Lee, J.M., Choo, Y.S., Fossale, E., Anderson, M., Gusella, J.F., Laramie, J.M., Myers, R.H., Lesort, M. et al. (2005) HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet., 14, 2871-2880.
32. Hervias, I., Beal, M.F. and Manfredi, G. (2006) Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve, 33, 598-608.
33. Browne, S.E. and Beal, M.F. (2006) Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox Signal., 8, 2061-2073.
34. Panov, A.V., Gutekunst, C.A., Leavitt, B.R., Hayden, M.R., Burke, J.R., Strittmatter, W.J. and Greenamyre, J.T. (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci., 5, 731-736.
35. Di Prospero, N.A. and Fischbeck, K.H. (2005) Therapeutics development for triplet repeat expansion diseases. Nat. Rev. Genet., 6, 756-765.
36. Thau, N., Knippenberg, S., Körner, S., Rath, K.J., Dengler, R. and Petri, S. (2012) Decreased mRNA expression of PGC-1a and PGC-1a-regulated factors in the SOD1G93A ALS mouse model and in human sporadic ALS. J. Neuropathol. Exp. Neurol., 71, 1064-1074.
37. Eschbach, J., Schwalenstöcker, B., Soyal, S.M., Bayer, H., Wiesner, D., Akimoto, C., Nilsson, A.C., Birve, A., Meyer, T., Dupuis, L. et al. (2013) PGC-1a is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Hum. Mol. Genet., 22, 3477-3484.
38. Kiaei, M., Kipiani, K., Chen, J., Calingasan, N.Y. and Beal, M.F. (2005) Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol., 191, 331-336.
39. Kiaei, M. (2008) Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral sclerosis and huntington's disease. PPAR Res., 2008, 418765.
40. Kalonia, H., Kumar, P. and Kumar, A. (2010) Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-upsilon (PPARUpsilon) in Huntington's disease. Pharmacol. Biochem. Behav., 96, 115-124.
41. Park, S.W., Yi, J.H., Miranpuri, G., Satriotomo, I., Bowen, K., Resnick, D.K. and Vemuganti, R. (2007) Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J. Pharmacol. Exp. Ther., 320, 1002-1012.
42. Landreth, G.E. and Heneka, M.T. (2001) Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol. Aging, 22, 937-944.
43. Wayman, N.S., Hattori, Y., McDonald, M.C., Mota-Filipe, H., Cuzzocrea, S., Pisano, B., Chatterjee, P.K. and Thiemermann, C. (2002) Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J., 16, 1027-1040.
44. Liu, H.R., Tao, L., Gao, E., Lopez, B.L., Christopher, T.A., Willette, R.N., Ohlstein, E.H., Yue, T.L. and Ma, X.L. (2004) Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc. Res., 62, 135-144.
45. Bright, J.J., Kanakasabai, S., Chearwae, W. and Chakraborty, S. (2008) PPAR regulation of inflammatory signaling in CNS diseases. PPAR Res., 2008, 658520.
46. Dupuis, L., Dengler, R., Heneka, M.T., Meyer, T., Zierz, S., Kassubek, J., Fischer, W., Steiner, F., Lindauer, E., Otto, M. et al. (2012) A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One, 7, e37885.
47. Hunt, M.J. and Morton, A.J. (2005) Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp. Brain Res., 166, 220-229.
48. Di Filippo, M., Chiasserini, D., Tozzi, A., Picconi, B. and Calabresi, P. (2010) Mitochondria and the link between neuroinflammation and neurodegeneration. J. Alzheimers Dis., 20, S369-S379.
49. Stommel, E.W., Van Hoff, R.M., Graber, D.J., Bercury, K.K., Langford, G.M. and Harris, B.T. (2007) Tumor necrosis factor-alpha induces changes in mitochondrial cellular distribution in motor neurons. Neuroscience, 146, 1013-1019.
50. Mauro, C., Leow, S.C., Anso, E., Rocha, S., Thotakura, A.K., Tornatore, L., Moretti, M., De Smaele, E., Beg, A.A., Tergaonkar, V. et al. (2011) NF-kB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat. Cell. Biol., 13, 1272-1279.
51. Mariappan, N., Elks, C.M., Sriramula, S., Guggilam, A., Liu, Z., Borkhsenious, O. and Francis, J. (2010) NF-kappaB-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes. Cardiovasc. Res., 85, 473-483.
52. Kaltschmidt, B. and Kaltschmidt, C. (2009) NF-kappaB in the nervous system. Cold Spring Harb. Perspect. Biol., 1, a001271.
53. Swarup, V., Phaneuf, D., Dupré, N., Petri, S., Strong, M., Kriz, J. and Julien, J.P. (2011) Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kB-mediated pathogenic pathways. J. Exp. Med., 208, 2429-2447.
54. Yates, L.L. and Górecki, D.C. (2006) The nuclear factor-kappaB (NF-kappaB): from a versatile transcription factor to a ubiquitous therapeutic target. Acta Biochim. Pol., 53, 651-662.
55. Sambataro, F. and Pennuto, M. (2012) Cell-autonomous and non-cell-autonomous toxicity in polyglutamine diseases. Prog. Neurobiol., 97, 152-172.
56. Ilieva, H., Polymenidou, M. and Cleveland, D.W. (2009) Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. Cell Biol., 187, 761-772.
57. Boillée, S., Yamanaka, K., Lobsiger, C.S., Copeland, N.G., Jenkins, N.A., Kassiotis, G., Kollias, G. and Cleveland, D.W. (2006) Onset and progression in inherited ALS determined by motor neurons and microglia. Science, 312, 1389-1392.
58. Beers, D.R., Henkel, J.S., Zhao, W., Wang, J. and Appel, S.H. (2008) CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. USA, 105, 15558-15563.
59. Henkel, J.S., Beers, D.R., Siklós, L. and Appel, S.H. (2006) The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol. Cell. Neurosci., 31, 427-437.
60. Kishida, K., Shimomura, I., Nishizawa, H., Maeda, N., Kuriyama, H., Kondo, H., Matsuda, M., Nagaretani, H., Ouchi, N., Hotta, K. et al. (2001) Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor gamma. J. Biol. Chem., 276, 48572-48579.
61. Waza, M., Adachi, H., Katsuno, M., Minamiyama, M., Sang, C., Tanaka, F., Inukai, A., Doyu, M. and Sobue, G. (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med., 11, 1088-1095.
62. Katsuno, M., Adachi, H., Minamiyama, M., Waza, M., Doi, H., Kondo, N., Mizoguchi, H., Nitta, A., Yamada, K., Banno, H. et al. (2010) Disrupted transforming growth factor-beta signaling in spinal and bulbar muscular atrophy. J. Neurosci., 30, 5702-5712.
63. Kobayashi, Y., Kume, A., Li, M., Doyu, M., Hata, M., Ohtsuka, K. and Sobue, G. (2000) Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem., 275, 8772-8778.
64. Adachi, H., Waza, M., Tokui, K., Katsuno, M., Minamiyama, M., Tanaka, F., Doyu, M. and Sobue, G. (2007) CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J. Neurosci., 27, 5115-5126.
65. Kondo, N., Katsuno, M., Adachi, H., Minamiyama, M., Doi, H., Matsumoto, S., Miyazaki, Y., Iida, M., Tohnai, G., Nakatsuji, H. et al. (2013) Heat shock factor-1 influences pathological lesion distribution of polyglutamine-induced neurodegeneration. Nat. Commun., 4, 1405.
66. Toyokuni, S., Tanaka, T., Hattori, Y., Nishiyama, Y., Yoshida, A., Uchida, K., Hiai, H., Ochi, H. and Osawa, T. (1997) Quantitative immunohistochemical determination of 8-hydroxy-2'-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab. Invest., 76, 365-374.